Aptevo Therapeutics Inc (NASDAQ:APVO) has received an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation.

Analysts have set a 1 year consensus price target of $6.17 for the company and are forecasting that the company will post ($0.24) earnings per share for the current quarter, according to Zacks. Zacks has also given Aptevo Therapeutics an industry rank of 90 out of 255 based on the ratings given to its competitors.

A number of equities analysts recently weighed in on APVO shares. Piper Jaffray Companies reduced their price target on Aptevo Therapeutics from $4.50 to $3.00 in a report on Friday, October 4th. ValuEngine raised Aptevo Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research cut Aptevo Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 16th.

In other news, Director Fuad El-Hibri bought 100,000 shares of Aptevo Therapeutics stock in a transaction on Monday, August 12th. The stock was acquired at an average price of $0.76 per share, with a total value of $76,000.00. Following the completion of the acquisition, the director now directly owns 1,124,536 shares of the company’s stock, valued at $854,647.36. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have acquired 180,015 shares of company stock valued at $140,662 in the last three months. Insiders own 11.74% of the company’s stock.

Several institutional investors have recently made changes to their positions in the business. Worth Venture Partners LLC raised its holdings in shares of Aptevo Therapeutics by 4.4% during the second quarter. Worth Venture Partners LLC now owns 447,669 shares of the biotechnology company’s stock valued at $397,000 after acquiring an additional 18,669 shares during the last quarter. Stonepine Capital Management LLC raised its holdings in shares of Aptevo Therapeutics by 0.7% during the second quarter. Stonepine Capital Management LLC now owns 3,922,891 shares of the biotechnology company’s stock valued at $3,478,000 after acquiring an additional 28,672 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Aptevo Therapeutics during the first quarter valued at approximately $33,000. Bank of New York Mellon Corp raised its holdings in shares of Aptevo Therapeutics by 256.3% during the second quarter. Bank of New York Mellon Corp now owns 56,620 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 40,728 shares during the last quarter. Finally, Algert Global LLC acquired a new position in shares of Aptevo Therapeutics during the second quarter valued at approximately $66,000. 32.90% of the stock is owned by institutional investors and hedge funds.

NASDAQ APVO remained flat at $$0.64 during trading hours on Monday. The company had a trading volume of 181,033 shares, compared to its average volume of 528,552. The stock has a market capitalization of $29.13 million, a price-to-earnings ratio of -0.27 and a beta of 2.46. Aptevo Therapeutics has a 12 month low of $0.49 and a 12 month high of $4.00. The company has a debt-to-equity ratio of 0.89, a current ratio of 2.63 and a quick ratio of 2.21. The firm has a fifty day moving average price of $0.63 and a 200-day moving average price of $0.78.

Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings results on Friday, August 9th. The biotechnology company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. The company had revenue of $7.36 million during the quarter, compared to analysts’ expectations of $6.95 million. Aptevo Therapeutics had a negative return on equity of 148.97% and a negative net margin of 195.98%. As a group, sell-side analysts expect that Aptevo Therapeutics will post -1.16 earnings per share for the current fiscal year.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.

Featured Article: Why do commodities matter?

Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.